Abstract
References
Articles referenced by this article (20)
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.
J Neuroimmunol, (1-2):163-172 2002
MED: 12225898
Interferon-beta is required for interferon-alpha production in mouse fibroblasts.
Curr Biol, (4):223-226 1998
MED: 9501984
Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study.
Brain, (Pt 3):616-627 2003
MED: 14691063
Experimental autoimmune encephalomyelitis: an animal model for multiple sclerosis
Neurosci. Res. Commun. 2000
Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers.
Brain, 365-378 1990
MED: 2328409
Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.
J Med Chem, (8):2075-2088 2004
MED: 15056005
Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis.
Ann Neurol, (5):661-669 1993
MED: 8239560
IFN-beta modulates specific T cell responses in vitro but does not affect Experimental Autoimmune Encephalomyelitis in the SJL mouse.
J Neuroimmunol, (1-2):190-196 1999
MED: 10695729
Attenuation of experimental autoimmune encephalomyelitis and nonimmune demyelination by IFN-beta plus vitamin B12: treatment to modify notch-1/sonic hedgehog balance.
J Immunol, (10):6418-6426 2004
MED: 15128833
Show 10 more references (10 of 20)
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Smart citations by scite.ai
Explore citation contexts and check if this article has been
supported or disputed.
https://scite.ai/reports/10.1016/j.jneuroim.2005.11.023
Article citations
Cortical and meningeal pathology in progressive multiple sclerosis: a new therapeutic target?
Rev Neurosci, 30(3):221-232, 01 Apr 2019
Cited by: 3 articles | PMID: 30048237
Review
Oral Therapies for Multiple Sclerosis.
Cold Spring Harb Perspect Med, 9(1):a032011, 02 Jan 2019
Cited by: 20 articles | PMID: 29500302 | PMCID: PMC6314072
Review Free full text in Europe PMC
Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model.
J Neuroinflammation, 15(1):183, 14 Jun 2018
Cited by: 28 articles | PMID: 29903027 | PMCID: PMC6002998
Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010.
CNS Drugs, 32(3):269-287, 01 Mar 2018
Cited by: 40 articles | PMID: 29600441
Review
Laquinimod in the treatment of multiple sclerosis: a review of the data so far.
Drug Des Devel Ther, 10:1111-1118, 14 Mar 2016
Cited by: 25 articles | PMID: 27042003 | PMCID: PMC4798201
Review Free full text in Europe PMC
Go to all (33) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Insight into the mechanism of laquinimod action.
J Neurol Sci, 306(1-2):173-179, 22 Mar 2011
Cited by: 88 articles | PMID: 21429524
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Am J Pathol, 180(1):267-274, 05 Dec 2011
Cited by: 90 articles | PMID: 22152994
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats.
J Neuroimmunol, 156(1-2):3-9, 01 Nov 2004
Cited by: 110 articles | PMID: 15465591
Oral laquinimod therapy in relapsing multiple sclerosis.
Expert Opin Investig Drugs, 18(7):985-989, 01 Jul 2009
Cited by: 20 articles | PMID: 19527103
Review
Type I interferon response in the central nervous system.
Biochimie, 89(6-7):770-778, 24 Feb 2007
Cited by: 65 articles | PMID: 17408841
Review